ATE520656T1 - Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten - Google Patents

Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten

Info

Publication number
ATE520656T1
ATE520656T1 AT06026414T AT06026414T ATE520656T1 AT E520656 T1 ATE520656 T1 AT E520656T1 AT 06026414 T AT06026414 T AT 06026414T AT 06026414 T AT06026414 T AT 06026414T AT E520656 T1 ATE520656 T1 AT E520656T1
Authority
AT
Austria
Prior art keywords
oxo
producing
pyrrolidine derivatives
relates
present
Prior art date
Application number
AT06026414T
Other languages
English (en)
Inventor
John Surtees
Didier Bouvy
Antoine Thomas
Yves Combret
Michael Frank
Gunther Schmidt
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE520656T1 publication Critical patent/ATE520656T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06026414T 2005-12-21 2006-12-20 Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten ATE520656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75407005P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
ATE520656T1 true ATE520656T1 (de) 2011-09-15

Family

ID=37963913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06026414T ATE520656T1 (de) 2005-12-21 2006-12-20 Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten

Country Status (4)

Country Link
US (1) US8338621B2 (de)
EP (1) EP1806339B1 (de)
AT (1) ATE520656T1 (de)
ES (1) ES2371351T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5100298B2 (ja) * 2007-10-11 2012-12-19 株式会社トクヤマ 光学活性α−スルホニルオキシカルボン酸アミド誘導体及びその製造方法
BRPI0912161A2 (pt) * 2008-05-30 2015-10-06 Ucb Pharma Sa composição farmacêutica na forma de um tablete
CA2741660A1 (en) * 2008-11-07 2010-05-14 Novabay Pharmaceuticals, Inc. Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
TW201124078A (en) 2009-12-22 2011-07-16 Du Pont Fungicidal 2-(bicyclic aryloxy) carboxamides
WO2012003427A2 (en) 2010-07-01 2012-01-05 Northwestern University Chiral synthesis of pyrrolidine core compounds en route to neuronal nitric oxide synthase inhibitors
WO2012087372A1 (en) 2010-12-22 2012-06-28 E. I. Du Pont De Nemours And Company Fungicidal 2-(bicyclic aryloxy)carboxamides
AU2013257707A1 (en) * 2012-05-08 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy
CN106478482A (zh) * 2013-06-19 2017-03-08 成都百途医药科技有限公司 一种奥拉西坦的合成方法
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CN104892483B (zh) * 2015-04-16 2017-05-24 广东赛烽医药科技有限公司 2‑氧代‑1‑吡咯烷手性衍生物的制备方法
ES2965746T3 (es) * 2015-05-25 2024-04-16 Suzhou Pengxu Pharmatech Co Ltd Procesos para producir brivaracetam
CN108689968B (zh) * 2015-05-25 2020-09-15 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成布瓦西坦中的用途
CN108101823A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
WO2020051796A1 (zh) * 2018-09-12 2020-03-19 上海宣泰医药科技有限公司 布瓦西坦的制备方法及其中间体
CN111333563B (zh) * 2018-12-19 2023-11-07 上海科胜药物研发有限公司 一种布瓦西坦中间体的制备方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US12522850B2 (en) 2019-12-19 2026-01-13 Abiochem Biotechnology (Group) Co., Ltd. Fluoroacetate dehalogenase mutant and application thereof
WO2021253162A1 (zh) * 2020-06-15 2021-12-23 浙江天宇药业股份有限公司 一种布瓦西坦的制备方法
CN111675643B (zh) * 2020-06-15 2021-10-26 浙江天宇药业股份有限公司 一种布瓦西坦的制备方法
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
CN115784959B (zh) * 2021-09-09 2025-05-27 凯特立斯(深圳)科技有限公司 一种布瓦西坦的制备方法
WO2023100110A1 (en) * 2021-12-02 2023-06-08 Macfarlan Smith Limited Process for preparing brivaracetam
CN114409586A (zh) * 2021-12-23 2022-04-29 山东诚汇双达药业有限公司 一种左乙拉西坦的制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
CN118993973B (zh) * 2024-10-22 2024-12-24 山东玉满坤生物科技有限公司 一种吡拉西坦的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
IL160045A0 (en) * 2001-08-10 2004-06-20 Ucb Sa Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
MXPA06014201A (es) 2004-06-11 2007-03-12 Ucb Sa Proceso para preparar derivados de 2-oxo-1-pirrolidina.

Also Published As

Publication number Publication date
ES2371351T3 (es) 2011-12-30
US20080009638A1 (en) 2008-01-10
EP1806339A1 (de) 2007-07-11
EP1806339B1 (de) 2011-08-17
US8338621B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
ATE520656T1 (de) Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten
DE602005002654D1 (de) Prozess zur Herstellung von Nano- und Mikrokapseln aus Spinnenseidenprotein
DE602006012274D1 (de) Verfahren und Vorrichtung zur Herstellung von Gruppe III Nitridkristall.
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
ATE473224T1 (de) Verfahren zur herstellung von nebivolol
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
DE60321331D1 (de) Hydrierkatalysator, herstellung davon und verfahren zur herstellung von gamma-butyrolacton aus maleinsäureanhydrid unter verwendung des katalysators
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
ATE413875T1 (de) Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
ATE343605T1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
DE502005001841D1 (de) Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
ATE368661T1 (de) Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
ATE445601T1 (de) Verfahren zur herstellung von carvedilol und seinen enantiomeren
DE602005000377D1 (de) Verfahren zur herstellung von n-alkyl-pyrrolidonen
DE602004001646D1 (de) Verfahren zur Herstellung von Pyran
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
ATE297893T1 (de) Verfahren zur herstellung von pyrrolidonen
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
DE602004010929D1 (de) Verfahren zur herstellung von n-substituierten phthalimiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties